{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:30:30Z","timestamp":1786516230910,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the therapeutic effects and dose adjustment patterns of sacubitril\/valsartan (SV) over time in patients undergoing maintenance hemodialysis (HD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data of end-stage renal disease patients receiving maintenance HD at our center were retrospectively reviewed. A total of 151 patients treated with SV were included. All patients were followed up regularly in the dialysis outpatient clinic. The clinical characteristics, biochemical parameters, and echocardiographic measurements were collected at baseline and during follow-up. The efficacy, safety, and dose adjustment patterns of SV therapy were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A six-month observation period was selected for analysis to ensure adequate follow-up while maximizing the number of eligible patients included in the study. SV dose reduction was observed in 62 patients, and 48 patients had discontinued concomitant antihypertensive medications. The greatest reduction in the proportion of patients receiving SV combined with other antihypertensive agents occurred at the fourth month after dialysis initiation (39.8%). Patients receiving SV without dose reduction and in combination with other antihypertensive drugs had higher interdialytic and intradialytic blood pressure, when compared with patients receiving SV monotherapy or reduced\/discontinued SV. The multivariate analysis identified diabetes mellitus [odds ratio [OR]: 3.085, 95% confidence interval [CI]: 1.137\u20138.376,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027], higher baseline N-terminal pro B-type natriuretic peptide (OR: 1.870, 95% CI: 1.109\u20133.152,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), and higher interdialytic weight gain-to-dry weight ratio (OR: 4.083, 95% CI: 1.763\u20139.457,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) as independent predictors of intradialytic hypotension. During follow-up, six composite events occurred in the SV combination or monotherapy group, while 13 composite events occurred in the SV dose reduction or discontinuation group. There was no significant difference between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world practice, the dose reduction or discontinuation of SV is common in HD patients. Clinicians should carefully balance individual risks and benefits, apply SV with caution, and closely monitor patients receiving this therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1804910","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:54:55Z","timestamp":1786514095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose reduction and discontinuation of sacubitril\/valsartan over time in patients undergoing maintenance hemodialysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Nephrology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.31083\/j.rcm2407185","article-title":"Management of cardiovascular diseases in chronic hemodialysis patients","volume":"24","author":"Zhang","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijcard.2017.01.015","article-title":"Cardiovascular impact in patients undergoing maintenance hemodialysis: clinical management considerations","volume":"232","author":"Chirakarnjanakorn","year":"2017","journal-title":"Int J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cardfail.2022.09.013","article-title":"Managing heart failure in patients on dialysis. State-of-the-art review","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e46486","DOI":"10.7759\/cureus.46486","article-title":"Advancements in heart failure management: a comprehensive narrative review of emerging therapies","volume":"15","author":"Sapna","year":"2023","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1198560","DOI":"10.3389\/fneph.2023.1198560","article-title":"Pathophysiological concepts and screening of cardiovascular disease in dialysis patients","volume":"3","author":"Echefu","year":"2023","journal-title":"Front Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jch.14422","article-title":"Effects of sacubitril\/valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"Wang","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10557-023-07481-w","article-title":"Sacubitril\/valsartan in dialysis patients: update on current perspectives","volume":"39","author":"Spatola","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/jch.14635","article-title":"Efficacy and safety of sacubitril\/valsartan after switching from azilsartan in hemodialysis patients with hypertension","volume":"25","author":"Iwashima","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/heq.2023.0038","article-title":"The 2021 chronic kidney disease epidemiology collaboration race-free estimated glomerular filtration rate equations in kidney disease: leading the way in ending disparities","volume":"8","author":"Charles","year":"2024","journal-title":"Health Equity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2215\/CJN.12141017","article-title":"Mechanisms, clinical implications, and treatment of intradialytic hypotension","volume":"13","author":"Reeves","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2147\/TCRM.S111635","article-title":"Predialysis hypotension is not a predictor for mortality in long-term hemodialysis patients: insight from a single-center observational study","volume":"12","author":"Huang","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"B18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin Auton Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/HJH.0000000000003972","article-title":"Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis","volume":"43","author":"Nguyen","year":"2025","journal-title":"J Hypertens"},{"key":"B20","first-page":"3439","article-title":"Effects and safety of sacubitril\/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients","volume":"14","author":"Wen","year":"2022","journal-title":"Am J Transl Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ii23","DOI":"10.1093\/ndt\/gfaa017","article-title":"Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes","volume":"35","author":"Pinter","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"955780","DOI":"10.3389\/fcvm.2022.955780","article-title":"Effects of sacubitril\/valsartan in ESRD patients undergoing hemodialysis with HFpEF","volume":"9","author":"Guo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"sfaf078","DOI":"10.1093\/ckj\/sfaf078","article-title":"The association of vascular access flow with sacubitril\/valsartan and left ventricular ejection fraction in hemodialysis patients with heart failure with reduced ejection fraction","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"892460","DOI":"10.3389\/fphar.2022.892460","article-title":"Molecular mechanisms of sacubitril\/valsartan in cardiac remodeling","volume":"13","author":"Mustafa","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2429237","DOI":"10.1001\/jamanetworkopen.2024.29237","article-title":"Sacubitril-valsartan in patients requiring hemodialysis","volume":"7","author":"Le","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2222841","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis","volume":"45","author":"Ding","year":"2023","journal-title":"Ren Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12872-024-03744-y","article-title":"Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9710965","DOI":"10.1155\/2016\/9710965","article-title":"Management of patient care in hemodialysis while focusing on cardiovascular disease events and the atypical role of hyper- and\/or hypotension: a systematic review","volume":"2016","author":"Khan","year":"2016","journal-title":"Biomed Res Int"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1804910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:54:56Z","timestamp":1786514096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1804910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2026.1804910"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1804910","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1804910"}}